tldrdailynews.com logo

Nektar Therapeutics Shares Surge on Eczema Drug Success

1 min read
Source: Investor's Business Daily
Nektar Therapeutics Shares Surge on Eczema Drug Success
Photo: Investor's Business Daily
TL;DR

Nektar Therapeutics' stock surged over 90% after successful midstage trial results for its eczema drug rezpegaldesleukin, which showed significant symptom improvement and demonstrated a new biological approach to treating inflammatory and autoimmune skin conditions.

Topics:businesshealthcare#autoimmune#clinical-trial#eczema#healthcare#nektar-therapeutics#rezpegaldesleukin
Share this article
  1. Small Biotech Launches After Hitting An Eczema Grand Slam  Investor's Business Daily
  2. Nektar Therapeutics Stock Doubles After Promising Eczema Drug Trial Results  Investopedia
  3. Investors sweet on Nektar as phase 2b eczema success doubles share price  Fierce Biotech
  4. Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025  Yahoo Finance
  5. Stocks to Watch: Nektar Therapeutics, Alset  MarketWatch

Want the full story? Read the original reporting

Read on Investor's Business Daily